Effects of raloxifene and alendronate on bone turnover as assessed by procollagen type I N-terminal propeptide.
Raloxifene decreases PINP into the lower half of the premenopausal reference interval; alendronate decreases PINP more, with approximately 60% of alendronate-treated women having PINP concentrations below the lower limit of the premenopausal reference interval.


BACKGROUND
The purpose of this study was to evaluate the distribution of serum procollagen type I N-terminal propeptide (PINP) concentrations in women with postmenopausal osteoporosis prior to treatment and after treatment with either raloxifene or alendronate for 12 or more months.


METHODS
Included were data from 1,323 postmenopausal women aged 45 to 87 years, collected at baseline or after treatment with either alendronate 10 mg/day or raloxifene 60 mg/day. These patients had participated in one of four clinical trials in which intact PINP was measured by radioimmunoassay (Orion Diagnostica). A premenopausal reference interval from 16.0 to 75.8 μg/L was determined from 68 premenopausal, non-pregnant women.


RESULTS
Most postmenopausal osteoporotic patients prior to treatment had PINP values in the upper half of the premenopausal reference interval at baseline (70%). After ≥ 12 months of therapy, most patients who received raloxifene had PINP concentrations in the lower half of the premenopausal reference interval (58%), whereas among those who received alendronate, around 60% of patients had PINP concentrations below the lower limit of the premenopausal reference interval.


CONCLUSIONS
PINP may be useful for assessing differences in bone turnover response to different types of anti-resorptive therapy.
Eastell
R
R
NIHR Bone Biomedical Research Unit, Centre for Biomedical Research, Northern General Hospital, Herries Road, Sheffield S5 7AU, UK. r.eastell@sheffield.ac.uk
Rogers
A
A
Ni
X
X
Krege
J H
JH
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D019386:Alendronate / Q000494:pharmacology* / Q000627:therapeutic use; D015415:Biomarkers / Q000097:blood; D050071:Bone Density Conservation Agents / Q000494:pharmacology*; D016723:Bone Remodeling / Q000187:drug effects*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008875:Middle Aged; D015663:Osteoporosis, Postmenopausal / Q000097:blood / Q000188:drug therapy / Q000503:physiopathology; D010446:Peptide Fragments / Q000097:blood*; D017697:Premenopause / Q000097:blood; D011347:Procollagen / Q000097:blood*; D020849:Raloxifene Hydrochloride / Q000494:pharmacology* / Q000627:therapeutic use; D012016:Reference Values; D016896:Treatment Outcome
D015415:Biomarkers; D050071:Bone Density Conservation Agents; D010446:Peptide Fragments; D011347:Procollagen; C047202:procollagen Type I N-terminal peptide; D020849:Raloxifene Hydrochloride; D019386:Alendronate